Investment case

Mesoblast Limited

MESO · 3 developments mapped · last assessed 2026-08-27

Market Ontology has mapped 3 macro, policy, and market developments to Mesoblast Limited since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

Last close

Unavailable

No published quote

Market cap

Unavailable

Equity value

Diluted shares

Unavailable

Latest reported

Sector

Unavailable

Listing

Unavailable

Filings

Unavailable

No published filing

Valuation

No validated run has been published for MESO yet, so no modelled value is shown. The MESO valuation is in the public catch-up queue.

Subscribers do not wait for the weekly cycle: they run MESO on demand, against live prices and the latest filings, and change any assumption the developments below move.

Filed financials

A validated filed-statement snapshot has not been published for MESO. Missing data is not estimated or replaced with scenario assumptions.

Continue this research

Value MESO on your own assumptions

Run the valuation on Mesoblast Limited, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run MESO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade MESO

Professional

Open trade discovery with Mesoblast Limited and MESO already in context.

Open

Find pricing gaps in MESO

Institutional

Open relative-value and arbitrage analysis with MESO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens MESO first, then any listed company you want to value or monitor.

Choose another company

Current case

Strongest support
Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch
Direct financial performance and successful commercialization of a key product, shifting investor perception from development-stage to revenue-generating.
2026-08-27 · Moves probability of success for commercial products, discount rate (reduced risk perception), terminal growth rate (due to established product line)
Open question
Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Direct financial performance and clinical trial progress update.
2026-08-27 · Moves revenue growth rate, probability of success for pipeline assets, future r&d expenses

What changed, by assumption

Probability of success for commercial products

2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch

Ryoncil peak sales estimates

2026-08-27Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch

Revenue growth rate

2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial

Event impact log

Full ledger →

Date	Mechanism	Direction	Horizon	Impact
2026-08-27	Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch	Bullish	3-12m	0.90
2026-08-27	Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch	Bullish	1-3m	0.80
2026-08-27	Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial	mixed	1-3m	0.70

Value MESO yourself$399/month

Continue this research

Value MESO on your own assumptions

Run the valuation on Mesoblast Limited, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run MESO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade MESO

Professional

Open trade discovery with Mesoblast Limited and MESO already in context.

Open

Find pricing gaps in MESO

Institutional

Open relative-value and arbitrage analysis with MESO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens MESO first, then any listed company you want to value or monitor.

Choose another company

Mesoblast Limited

MESO · 3 developments mapped · last assessed 2026-08-27

Value MESO on your own assumptions

Run the valuation on Mesoblast Limited, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run MESO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade MESO

Professional

Open trade discovery with Mesoblast Limited and MESO already in context.

Open

Find pricing gaps in MESO

Institutional

Open relative-value and arbitrage analysis with MESO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens MESO first, then any listed company you want to value or monitor.

Choose another company

Date

Mechanism

Direction

Horizon

Impact

2026-08-27

Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch

Bullish

3-12m

0.90

2026-08-27

Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch

Bullish

1-3m

0.80

2026-08-27

Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial

mixed

1-3m

0.70

Value MESO on your own assumptions

Run the valuation on Mesoblast Limited, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run MESO on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade MESO

Professional

Open trade discovery with Mesoblast Limited and MESO already in context.

Open

Find pricing gaps in MESO

Institutional

Open relative-value and arbitrage analysis with MESO already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens MESO first, then any listed company you want to value or monitor.

Choose another company